Address: 823 Jays Drive
Lansdale, PA 19446,United States of America
Tel:
Web: http://www.jdptherapeutics.com/default.aspx
JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life-threatening diseases with significant unmet medical needs, primarily for use in acute care in a hospital setting.
Small Molecule Therapeutics
With US still the reigning global champion in biotech innovation, the dynamic and vibrant biopharma ecosystem in the world’s largest healthcare market continues to churn out ground-breaking innovations with companies…
Michael Ciarametaro, VP for Research at the US National Pharmaceutical Council (NPC), outlines issues surrounding the outdated Medicaid Best Price (MBP) and why there is a dire need for payment…
Following PharmaBoardroom’s recent interview with Ivan Cheung, chairman of Eisai’s US affiliate and president of Eisai’s global neurology business, we take the opportunity to look back on the interesting history…
Karyopharm Therapeutics’ Dr Michael G. Kauffman outlines the genesis of the company he co-founded with his wife, the approval journey of key product XPOVIO®, his ambitious internationalisation plans, and the…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung…
Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech companies failing to develop effective treatments for…
PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted the long-term damage COVID-19 is causing to the general mental health…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s specialty portfolio in the US market, the challenges of…
Executives from ALK, Sanofi Genzyme and Novartis discuss how they are navigating pricing and reimbursement issues in the USA, home to the world’s largest – but perhaps most complex –…
With COVID-19 having wreaked havoc on global operations, the pharma industry is understandably focused on leveraging its collective resources and knowhow in discovering and delivering prophylactics and therapeutics against the…
Ameet Mallik, Executive VP and Head of Oncology for the US at Novartis Oncology highlights the company’s culture of ‘curious, inspired, and unbossed,’ how Novartis differentiates itself in a highly…
See our Cookie Privacy Policy Here
